GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » Earnings per Share (Diluted)

Cannara Biotech (TSXV:LOVE) Earnings per Share (Diluted) : C$0.06 (TTM As of Aug. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Earnings per Share (Diluted)?

Cannara Biotech's Earnings per Share (Diluted) for the three months ended in Aug. 2024 was C$0.06. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Aug. 2024 was C$0.06.

Cannara Biotech's EPS (Basic) for the three months ended in Aug. 2024 was C$0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Aug. 2024 was C$0.06.

Cannara Biotech's EPS without NRI for the three months ended in Aug. 2024 was C$0.06. Its EPS without NRI for the trailing twelve months (TTM) ended in Aug. 2024 was C$0.04.

During the past 12 months, Cannara Biotech's average EPS without NRIGrowth Rate was -35.80% per year.

During the past 7 years, Cannara Biotech's highest 3-Year average EPS without NRI Growth Rate was -48.40% per year. The lowest was -48.40% per year. And the median was -48.40% per year.


Cannara Biotech Earnings per Share (Diluted) Historical Data

The historical data trend for Cannara Biotech's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Earnings per Share (Diluted) Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Earnings per Share (Diluted)
Get a 7-Day Free Trial -0.20 -0.10 0.03 0.08 0.07

Cannara Biotech Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.02 -0.04 0.02 0.06

Competitive Comparison of Cannara Biotech's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's PE Ratio falls into.



Cannara Biotech Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Cannara Biotech's Earnings Per Share (Diluted) for the fiscal year that ended in Aug. 2024 is calculated as

Diluted Earnings Per Share (A: Aug. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(6.438-0)/91.385
=0.07

Cannara Biotech's Earnings Per Share (Diluted) for the quarter that ended in Aug. 2024 is calculated as

Diluted Earnings Per Share (Q: Aug. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(5.754-0)/91.524
=0.06

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Cannara Biotech  (TSXV:LOVE) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cannara Biotech Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
Executives
Nicholas Sosiak Senior Officer
Olymbec Investments Inc. 10% Security Holder
Derek Elan Stern Director
Donald John Olds Director
Scott Carroll Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Zohar Krivorot Director, Senior Officer
Brian Sherman Senior Officer
Avi Krivorot Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Lennie Ryer Senior Officer
Jack M. Kay Director
Donal Carroll Director or Senior Officer of 10% Security Holder